Hidden Targets in RAF Signalling Pathways to Block Oncogenic RAS Signalling

Oncogenic RAS (Rat sarcoma) mutations drive more than half of human cancers, and RAS inhibition is the holy grail of oncology. Thirty years of relentless efforts and harsh disappointments have taught us about the intricacies of oncogenic RAS signalling that allow us to now get a pharmacological grip...

Descripción completa

Detalles Bibliográficos
Autores principales: Nolan, Aoife A., Aboud, Nourhan K., Kolch, Walter, Matallanas, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070103/
https://www.ncbi.nlm.nih.gov/pubmed/33920182
http://dx.doi.org/10.3390/genes12040553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070103/
https://www.ncbi.nlm.nih.gov/pubmed/33920182
http://dx.doi.org/10.3390/genes12040553

Ejemplares similares